Inestom

Levocarnitine, the active ingredient in Inestom, is a Carnitine presented as an intravenous solution for intravenous use. It treats primary systemic carnitine deficiency, secondary carnitine deficiency in dialysis patients, and fatty acid oxidation disorders in individuals with documented carnitine deficiency. The compound restores intracellular carnitine stores, supporting normal fatty‑acid metabolism and cellular energy production in patients with impaired carnitine synthesis or increased loss.

GNH USA supplies Inestom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and specialty clinics worldwide.

Inestom (levocarnitine) is used to address metabolic conditions related to carnitine deficiency. - Primary systemic carnitine deficiency: restores carnitine levels to improve fatty‑acid oxidation and energy metabolism. - Secondary carnitine deficiency (e.g., dialysis patients): supplements lost carnitine to support metabolic stability. - Fatty acid oxidation disorders: provides essential carnitine for mitochondrial β‑oxidation in affected individuals. - Metabolic support in certain inherited disorders: assists in maintaining cellular energy production where carnitine metabolism is impaired.

Levocarnitine administered intravenously may be associated with the following adverse reactions.

Common Side Effects: - Nausea: mild stomach upset that may resolve spontaneously. - Vomiting: occasional emesis following infusion. - Headache: transient headache during or after administration. - Flushing or warmth sensation: brief skin reddening or feeling of heat. - Hypotension or transient blood pressure drop: temporary decrease in blood pressure. - Fever or chills: mild pyrexia or shivering post‑infusion.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions: hives, swelling, respiratory distress requiring emergency care. - Severe hypotension requiring medical intervention: marked blood pressure fall needing treatment. - Cardiac arrhythmias: irregular heart rhythm observed during monitoring. - Metabolic acidosis: significant pH imbalance in blood. - Electrolyte disturbances (e.g., hyperkalemia): abnormal potassium levels. - Seizures (rare): convulsive episodes reported infrequently.

When using Inestom, clinicians should observe the following precautions to ensure safe administration. - Monitor plasma carnitine levels: adjust dosage based on measured concentrations. - Adjust dose in renal impairment: reduced clearance may require lower infusion rates. - Use caution in patients with cardiac disease: monitor hemodynamic status during infusion. - Avoid rapid infusion: administer over recommended time to prevent hypotension. - Observe for allergic reactions: discontinue infusion if signs of hypersensitivity appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine may interact with certain medications; the following interactions are recognized.

Major Interactions (Avoid): - Valproic acid: may deplete carnitine stores, reducing therapeutic effect. - High-dose anticoagulants: potential increased bleeding risk when combined with levocarnitine.

Moderate Interactions (Monitor Closely): - Pivalic acid‑containing antibiotics (e.g., pivampicillin): increase urinary carnitine loss. - Insulin therapy: may enhance hypoglycemia; monitor glucose levels. - Loop diuretics: can affect electrolyte balance; watch potassium. - Other intravenous nutrition solutions: assess compatibility before co‑administration.